In this study, we investigated the role of interleukin-lp (IL-1s) in the malignant evolution of chronic myelogenous leukemia (CML) and the functional activity of IL-1 inhibitors. Bone marrow (BM) and peripheral blood (PB) low-density cells from 38 CML patients were studied in the colonyforming unit-granulocyte, erythrocyte, monocyte, megakaryocyte colony culture assay. Samples from patients with early stage, interferon-a (IFN)-sensitive disease formed hematopoietic colonies in the presence of fetal calf serum (FCS), erythropoietin (Epo), and one of the following: granulocyte-macrophage colony-stimulating factor (10 ng/mL), IL-3 (15 ng/mL), both, or phytohemagglutinin-conditioned medium. The addition of IL-1p augmented IFN-sensitive CML colony growth in a dose-dependent manner at concentrations of 10 to 100 U/mL. In sharp contrast, addition of the above growth factors did not augment the colony growthpromoting effect of FCS and Epo in samples from IFNresistant patients; further, adherent cell fractionation or HRONIC MYELOGENOUS leukemia (CML) is a C myeloproliferative disorder characterized by a chronic stage, which is followed by an accelerated phase and blastic tran~formation.'.~ Several studies have demonstrated that interferon-a (IFN) can induce durable partial or complete remissions in low-risk CML patients with evidence of Ph' chromosome ~uppression.~-'~ However, the incidence of response to IFN treatment significantly decreases when the drug is administered to high-risk patients'' and to patients with long-standing d i s e a~e .~ Interleukin-1 (IL-1) is a term used for two polypeptide hormones (IL-la and IL-1p) that possess a wide spectrum of biologic activities. The cDNA for human IL-la was first reported by Auron et allz and for IL-lp by Lomedico et all3 in 1984. Both genes for IL-la and IL-lP were c l~n e d '~~'~ and located on the long arm of chromosome 2.16 Although these two proteins share only a 26 amino acid homology, they bind to the same receptor and share identical biologic propertie~.'~.'~ IL-16 is the prominent form of IL-1, and the amount of IL-lp messenger RNA (mRNA) found in and IL-1 receptor antagonist (IL-1RA) at concentrations of 5 t o 100 ng/mL(slL-1R) and 10 to 500 ng/mL (IL-'IRA) inhibited CML colony growth in a dose-dependent fashion, with maximal inhibition of 64% and 65%. respectively. A similar effect was noted with the use of anti-IL-lp neutralizing antibodies. These data implicate IL-1p in CML disease progression and suggest that the inhibitory effects of molecules such as slL-1R and IL-1RA could conceivably be the basis of a novel therapeutic strategy against this disorder.
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T-lymphocyte depletion attenuated the "autonomous" colony growth. Lysates of 2.5 x lo7 low-density cells from each of six IFN-resistant and six IFN-sensitive CML patients and three normal volunteers were tested for intrinsic IL-1p content in an enzyme-linked immunosorbent assay and yielded a mean of 610 pg, 54.6 pg, and 49.4 pg of IL-lp, respectively (P < .045). Interestingly, both soluble IL-1 receptors (slL-1R) and IL-1 receptor antagonist (IL-1RA) at concentrations of 5 t o 100 ng/mL(slL-1R) and 10 to 500 ng/mL (IL-'IRA) inhibited CML colony growth in a dose-dependent fashion, with maximal inhibition of 64% and 65%. respectively. A similar effect was noted with the use of anti-IL-lp neutralizing antibodies. These data implicate IL-1p in CML disease progression and suggest that the inhibitory effects of molecules such as slL-1R and IL-1RA could conceivably be the basis of a novel therapeutic strategy against this disorder. activated cells is usually 10-to 50-fold greater than the IL-1 has been implicated in the regulation of early events in hematopoiesis. It has been shown to synergize with other growth factors (GFs), possibly through the upregulation of colony-stimulating factor receptor^,"^^ and to enhance both human and murine primitive noncycling hematopoietic progenitor cell proliferation.m.21*25.26 Moreover, IL-1 can stimulate the production and release of hematopoietic GFs from a number of different accessory cell^,^^"^ thereby augmenting stimulation of hematopoietic progenitor multi-IFN (a or y) reduces IL-1 synthesis and gene expression in mononuclear cells stimulated by IL-1 itThus, part of the efficacy of IFN therapy in CML may include the suppressive effect of IFN in IL-1 autocrine loops.
In this study we found that low-density cells from IFN-resistant CML patients produce relatively large quantities of IL-lp, an event that may provide a growth advantage for the leukemic clone. Further, the inhibition of IL-1p activity by either soluble IL-1 receptors (sIL-1R) or IL-1 receptor antagonist (IL-IRA) (a naturally occurring molecule) significantly reduced CML hematopoietic colony proliferation. It is therefore possible that the growthinhibitory effect of these molecules on CML cells could be exploited as a new therapeutic modality.
IL-la f 0~m . I~

MATERIALS AND METHODS
Subjects.
Peripheral blood (PB) samples and bone marrow (BM) aspirates were obtained from 38 CML patients who did not receive any treatment for at least 2weeks. All 38 patients studied fit the classical clinical and laboratory description of CML38-42 (Table  1) . Eighteen patients were IFN-sensitive and 20 were IFNresistant. For control studies, BM was obtained from hematologically normal patients in whom BM aspiration was performed as part of a medical investigation, and PB was obtained from hematologically normal volunteers. These studies were performed with informed consent and were approved by the Human Experimentation Committee of our Institution. CML patients were defined as IFN-sensitive if they achieved complete or partial hematologic remissi0n.4.~' Patients who failed to demonstrate a decrease in their white blood cell (WBC) count to a level consistent with partial hematologic response and those who demonstrated an increase in count during the course of therapy were defined as having IFN-resistant CML.
Heparinized PB or BM cells were layered over Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ) and centrifuged at 400g for 20 minutes at 4°C to remove neutrophils and red blood cells (RBCs).
Low-density mononuclear cells were incubated in plastic tissue culture dishes or flasks (Falcon Plastics, Becton Dickinson, Oxnard, CA) with 10% fetal calf serum (FCS; Preparation ofcells.
Adherent cellfractionation.
Flow Laboratories, McLean, VA) in a-medium. The procedure was repeated until no more cells adhered to the tissue culture dishes. Nonadherent cells harvested in this way contained less than 3% monocytes, as confirmed by the following techniques: microscopic differential count of up to 200 cells prepared with Wright's stain, nonspecific (a-naphthyl butyrate) esterase staining, and immunocytochemical analysis using CD14 (My-4) monoclonal antibodies (MoAbs; Coulter Immunology, Hialeah, FL) to identify monocyte-promonocyte cells, as previously described."s45 T cells were depleted from the nonadherent fraction by a panning te~hnique.4"~' Briefly, nonadherent cells were incubated with saturating quantities (100 ng/106 cells) of CD3 MoAbs (Becton Dickinson) for 1 hour at 4°C. Labeled cells were washed three times to remove excess antibody before panning. Anti-Ig plates were prepared by incubating 100 x 15 mm plastic
T-cell depletion.
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From culture plates (Falcon, Becton Dickinson and Co, Lincoln Park, NJ) with 5 mL affinity-purified rabbit antimouse Ig (Serotec Ltd, Oxford, UK) 100 kg/mL in phosphate-buffered saline (PBS) overnight at 4°C and washed with cold PBS before use. Antibodylabeled cells were resuspended in 5 mL PBS, 5% heat-inactivated FCS (lo7 cellsiml), and incubated over the coated plates for 1 hour at 4"C, after which the antibody-negative cells were recovered by gentle pipetting.
Colony-fomzing unit-granulocyte, erythrocyte, monocyte, megakaryocyte (CFU-GEMM) assay. The CFU-GEMM assay we used is a modification of the assay described by Fauser and M e s~n e r .~'~~ In brief, 2 X lo5 nucleated low density BM or PB cells were cultured in 0.8% methylcellulose with Iscove's modified Dulbecco's medium (IMDM; GIBCO, Grand Island, NY), 30% FCS (Flow), 5% leukocyte-conditioned medium prepared with phytohemagglutinin (PHA-LCM)?' recombinant granulocyte-macrophage colonystimulating factor (GM-CSF) 10 ngimL or IL-3 15 ngimL or both (Immunex Corp, Seattle, WA) and human erythropoietin (Epo) 1.0 UimL (British Columbia Cancer Research Institute, Vancouver, Canada). Recombinant IL-lp 10 to 100 UimL (molecular weight [MW] 17,500; Boehringer Manneheim Biochemicals, Indianapolis, IN) was used in some experiments, and 100 ngimL of anti-IL-lp neutralizing antibodies (Genzyme Corporation, Boston, MA) were used to negate its effect. In another set of experiments, sIL-1Rs (Immunex Corp) were added to cultures at concentrations of 0.1 to 100 ng/mL, and in similar cultures we tested the effect of IL-1RA (IL-1RA protein; The Upjohn Company, Kalamazoo, MI) at concentrations of 10 to 500 ngimL. One milliliter of the culture mixture was placed in 35-mm Petri dishes (LUX, Nunc Inc, Naperville, IL) and incubated at 37°C with 5% CO, in air in a humidified atmosphere in duplicate. All cultures were evaluated after 14 days for the number of burst-forming unit-erythroid (BFU-E) colonies (defined as an aggregate of more than 500 hemoglobinized cells), or three or more erythroid subcolonies), CFU-granulocyte-macrophage (CFU-GM) colonies of 40 or more granulocyte or monocyte-macrophage cells or both, and mixed colonies containing all elements. Individual colonies were plucked from the cultures with a micropipette and analyzed for cellular composition.
The ELISA assay was performed using an IL-1p ELISA Kit (Cistron Biotechnology, Pine Brook, NJ). To avoid exposure to tissue culture conditions that may affect IL-1 production, fresh low-density BM or PB cells (5 x lo7) were frozen in 0.25 mL PBS at -20°C. All samples were thawed and frozen in liquid nitrogen three times and then centrifuged at 400g for 10 minutes to remove cell debris. Cell lysates and standard dilutions of IL-1p (20,50, 100, 200,500, and 1,000 pg/mL) were added to the test wells in duplicate and incubated for 2 hours at 37°C in 5% CO,. The test wells were then washed three times with PBS and incubated with rabbit IL-1p antiserum for 2 hours, washed as previously described, and incubated for 30 minutes with goat antirabbit IgG conjugated to horseradish peroxidase enzyme. A substrate (0-phenylenediamine dissolved in 3% hydrogen peroxide solution) was added to the test wells after vigorous washing and then 4N sulfuric acid was added. The color intensity was read within 15 minutes at a wave length of 490 nm using a microplate autoreader (Model no. EL-309; BIO-TEK Instruments, Vimooski, VT). The average net optical density (OD) of the standard IL-1p concentration was plotted. The amount of IL-p in each sample was determined by interpolation from the standard curve.
Statistical analysis. The statistical significance of differences between colony numbers was determined by Student's t-test, and the nonparametric test that corresponds to the parametric t-test (Mann-Whitney) was used to determine the statistical significance of differences between IL-1p concentrations.
IL-1 p enzyme-linked immunosorbent assay (ELISA).
RESULTS
Growth requirement of hematopoietic colonies from IFNresistant and from IFN-sensitive CML patients. When studied in the CFU-GEMM colony culture assay, BM or PB low-density cells from most IFN-sensitive CML patients gave rise to BFU-E and CFU-GM colonies only in the presence of FCS, Epo, and one of the following: PHA-LCM, GM-CSF, IL-3, or GM-CSF plus IL-3. In contrast, in IFN-resistant patients, addition of colony-stimulating factors did not augment colony growth-promoting effect of FCS and Epo (Figs 1 and 2) . This divergent growth pattern was prominent and the difference between the number of For
grown in the presence and absence of G F in the two groups of patients was statistically significant with the following GFs: PHA-LCM (P < .013 for RFU-E progenitors and P < .001 for CFU-GM), GM-CSF (P < . 0 1 for RFU-E and P < .O1 for CFU-GM), IL-3 (P < .01S for RFU-E and P < .001 for CFU-GM), and GM-CSF plus IL-3 (P < .007 for BFU-E and P < .003 for CFU-GM). A similar difference in colony growth pattern between the two groups of patients was observed also with CFU-GEMM colonies (data not shown). In the presence of exogenous GF, low-density cells from IFN-resistant and IFN-sensitive patients yielded similar numbers of colonies.
To evaluate the growth advantage of BM and PB cells from IFN-rcsistant CML patients, we cultured low-density cells from two IFN-rcsistant patients in the presence and absence of an exogenous growth factor (GM-CSF) after adherent cell fractionation and T-lymphocyte depletion (Fig 3) . Hematopoictic colony proliferation from these two IFN-resistant patients became G F dependent when adhcrent cells, T lymphocytes, or both were depleted, indicating that the "autonomous" colony growth observed in BM or PB cultures from IFN-resistant patients was mediated through accessory cells.
Ttic effect of the aicpcnted production of IL-IP by IFNresistant CML cell.7 on CML stem cell proliferation. To further delineate the growth advantage of cells from IFNresistant CML patients, we studied the effect of IL-lp on BFU-E and CFU-GM colony growth. When added to cultures in the absence of an cxogcnous growth factor (Table 2) , IL-lp did not affect colony growth in cultures from IFN-resistant patients, whereas it stimulated colony proliferation of IFN-scnsitive patients in a dose-responsive fashion (Fig 4) . This stimulatory effect was statistically These experiments were performed on low-density cells in the presence of FCS and Epo and in the absence of exogenous GF. IL-1p was added to the culture at a final concentration of 100 UlmL. Mean numbers of colonies from duplicate cultures are presented.
Abbrevietions: S, sensitive; R, resistant.
significant at an IL-lpconcentrationof 1 0 U I m L ( P < .017 for BFU-E and P < . 0 1 for CFU-GM colonies).
To test the hypothesis that IL-IP is overproduced in cells from IFN-resistant patients, thus providing a growth advantage either by enhancing the stimulatory effect of GFs that arc already present in the culture system or by stimulating G F production, we first tested the effect of anti-IL-lp neutralizing antibodies on IFN-resistant CML "autonomous" colony proliferation. Anti-IL-1 p neutralizing antibodies reduced colony numbers by 49% (BFU-E) and SS% (CFU-GM), and this effect was partially reversed by IL-lf.3 (Fig 5 ) .
We then measured the intracellular content of IL-lP by assaying lysates of cells from IFN-sensitive and IFNresistant CML patients. It was shown that in contrast to IL-la, IL-lp does not remain cell-associated and is se-
ACF and T-DapI. EFU-E ( . I and CFU-GM (01 colony proliferation. Two experiments were performed using low-density cells from patients 27 and 28. In patient 27 the mean number of EFU-E colonies in the presence of PHA-LCM was97, and the mean number of CFU-GM colonies was 111.
In the absence of GF (control) the mean number of EFU-E colonies was 94 and the mean number of CFU-GM colonies was 109. In patient 28
the mean number of EFU-E colonies in the presence of GM-CSF (10 mglmL) was 158, and the mean number of CFU-GM colonies was 171.
In the absence of GF the mean number of BFU-E colonies was 161 and the mean number of CFU-GM was 165. The data are presented as the percentage of control. For forming cclls. In culturcs from IFN-rcsistant CML paticnts, slL-l R rcduccd BFU-E colony prolifcration hy 38% (P < .O3) and CFU-GM colonics by 44% (P < . 0 2 S ) at a concentration of 100 nglmL. In thc ahscncc of cxogcnous GF, sIL-IR rcduccd RFU-E colonics hy 61% (P < .OOI) and CFU-GM colonics by 64% (P < .OO17) at thc samc conccntration (Fig 6) . Similarly, IL-IRA inhihitcd colony growth of cclls ohtaincd from two othcr IFN-rcsistant patients. At a concentration of S O ng/mL, IL-IRA inhihitcd BFU-E colony prolifcration hy 40% (P < .O2) and CFU-CM by 42% (P < .002) in thc prcscncc of colonystimulating activity. In thc ahscncc of addcd GF, BFU-E growth was inhihitcd hy 62% (P < .O1) and CFU-GM by 65% (P < .MI) (Fig7), suggesting that thc inhihitory cffcct cxcrtcd hy thcsc molcculcs can hc partially rcvcrscd hy an cxogcnous G F (GM-CSF or PHA-LCM). Wc thcn cxamincd thc cffcct of slL-IR and IL-IRA on colony-forming cclls from scvcn IFN-resistant CML paticnts, six IFN-scnsitivc CML paticnts, and six normal donors, with and without GF, in thc prcscncc and ahscncc of IL-lp (Tahlc 4). Both slL-IR and IL-IRA inhihitcd CML BFU-E and CFU-GM colony growth. The inhihitory cffcct cxcrtcd hy thcsc molcculcs on normal hcmatopoictic colony prolifcration was minimal. slL-1 R was significantly morc inhihitory on IFN-rcsistant CML cclls than o n normal samplcs (P < .OI for BFU-E and P < .03 for CFU-GM in thc ahscncc of GF, and P < .OS for BFU-E and CFU-GM in thc prcscncc of GF). Similarly, IL-IRA was significantly more cffcctivc on IFN-resistant CML than on normal progenitors (P < . O l S for BFU-E and P < .Wl for CFU-GM in thc abscncc of GF. and P < .W7 for BFU-E and P < .OOS for CFU in thc prcscncc of GF). The forming cclls. In culturcs from IFN-rcsistant CML paticnts, slL-l R rcduccd BFU-E colony prolifcration hy 38% (P < .O3) and CFU-GM colonics by 44% (P < . 0 2 S ) at a concentration of 100 nglmL. In thc ahscncc of cxogcnous GF, sIL-IR rcduccd RFU-E colonics hy 61% (P < .OOI) and CFU-GM colonics by 64% (P < .OO17) at thc samc conccntration (Fig 6) . Similarly, IL-IRA inhihitcd colony growth of cclls ohtaincd from two othcr IFN-rcsistant patients. At a concentration of S O ng/mL, IL-IRA inhihitcd BFU-E colony prolifcration hy 40% (P < .O2) and CFU-CM by 42% (P < .002) in thc prcscncc of colonystimulating activity. In thc ahscncc of addcd GF, BFU-E growth was inhihitcd hy 62% (P < .O1) and CFU-GM by 65% (P < .MI) (Fig7), suggesting that thc inhihitory cffcct cxcrtcd hy thcsc molcculcs can hc partially rcvcrscd hy an cxogcnous G F (GM-CSF or PHA-LCM). Wc thcn cxamincd thc cffcct of slL-IR and IL-IRA on colony-forming cclls from scvcn IFN-resistant CML paticnts, six IFN-scnsitivc CML paticnts, and six normal donors, with and without GF, in thc prcscncc and ahscncc of IL-lp (Tahlc 4). Both slL-IR and IL-IRA inhihitcd CML BFU-E and CFU-GM colony growth. The inhihitory cffcct cxcrtcd hy thcsc molcculcs on normal hcmatopoictic colony prolifcration was minimal. slL-1 R was significantly morc inhihitory on IFN-rcsistant CML cclls than o n normal samplcs (P < .OI for BFU-E and P < .03 for CFU-GM in thc ahscncc of GF, and P < .OS for BFU-E and CFU-GM in thc prcscncc of GF). Similarly, IL-IRA was significantly more cffcctivc on IFN-resistant CML than on normal progenitors (P < . O l S for BFU-E and P < .Wl for CFU-GM in thc abscncc of GF. and P < .W7 for BFU-E and P < .OOS for CFU in thc prcscncc of GF). The In patient 28 the mean number of BFU-E colonies in the presence of PHA-LCM was 158 and the mean number of CFU-GM colonies was 131. In the absence of PHA-LCM, the mean number of BFU-E colonies was 149 and the mean number of CFU-GM colonies was 125. In patient 29 the mean number of BFU-E colonies in the presence of GM-CSF was 104 and the mean number of CFU-GM colonies was 115. In the absence of GM-CSF, the mean number of BFU-E colonies was 98 and the mean number of CFU-GM colonies was 108.
INHIBITION OF IL-I IN CML
1481
etic colonies was shown to increase 500% in cultures containing CML serum. Finally, in a prospective study, cells from CML patients who later developed blastic crisis showed specific in vitro proliferative advantage months before blastic crisis occurred? indicating that the biologic events abetting disease progression are already present in the advanced chronic stage.
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We found that colony-forming cells from IFN-resistant patients proliferated in the presence of FCS and Epo alone.
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---'--I PHA-LCM, GM-CSF, and IL-3 at effective concentrations did not significantly increase hematopoietic colony numbers in samples from IFN-resistant patients but did in- colony growth inhibition of sIL-1R and IL-1RA was again less effective in the presence of GF (either GM-CSF or PHA-LCM) and the inhibitory effect was partially reversed by IL-1P.
DISCUSSION
In recent years, various studies have shown that CML cells have a growth advantage in culture.s2 When CML blood cells were cocultured on a pre-established normal marrow-adherent layer, Ph'-positive progenitors proliferated continuously. In contrast, their normal counterparts had to be activated by the addition of horse serum or factors such as 1L-1 or platelet-derived GF (PDGF).53 Evidence for a CML-derived growth-stimulatory effect was presented in another study? in which the number of 35-day hematopoicolonies from CML patients originate from the leukemic c 1 0 n e .~~~~~ It is therefore unlikely that this divergent growth pattern results from dissimilar growth requirements of CML and normal progenitor colony-forming cells.
Because IFN-resistant CML patients are believed to represent a more advanced stage of disease progression than IFN-sensitive patients:' it appears that an autocrine or paracrine mechanism might be operative. In agreement with previous studies,46,58-61 we found that neither CFU-GM nor BFU-E CML colonies proliferate autonomously. Depletion of adherent cells or T lymphocytes abrogated the "autonomous" colony proliferation of IFN-resistant CML, suggesting that CML progenitor colony-forming cells from these patients are GF dependent and proliferate in response to colony-stimulating factors released by accessory cells. However, myeloid colony-stimulating factors (GM-CSF, G-CSF, M-CSF, and IL-3) are not overexpressed in BM and PB mononuclear cells from CML patients.62 Therefore, a cytokine that induces production of GFs and/or enhances the effect of GFs already present in culture could mediate the growth advantage exhibited by IFN-resistant CML patients' cells. Because IL-1 possesses these p r~p e r t i e s ,~~~~~~~~.~ we tested the effect of IL-1P in our culture system and found that whereas it stimulated proliferation of colony-forming cells from IFN-sensitive patients in a dose-dependent manner, it had no effect on IFNresistant CML colony growth. We assumed that IFN- BFU-E CFU-GM BFU-E CFU-GM BFU-E CFU-GM BFU-E CFU-GM BFU-E CFU-GM BFU-E CFU-GM BFU-E CFU-GM BFU-E CFU-GM resistant CML colony-forming cells were maximally stimulated by endogenous IL-lp, and addition of exogenous IL-1p could not further increase colony growth as it did in IFN-sensitive CML. We have therefore tested the effect of anti-IL-lp neutralizing antibodies on BFU-E and CFU-GM colony-forming cells from two IFN-resistant patients and found a 50% inhibition of IFN-resistant CML colony growth. The addition of IL-lp partially reversed the inhibitory effect, thus proving its specificity. We then measured the amount of IL-lp in cell lysates and found that lowdensity cells from IFN-resistant patients produce significantly more IL-lf3 than cells from IFN-sensitive patients or cells from hematologically normal individuals. These data are meaningful even if both IL-1p and precursor IL-lp (pro-IL-16) were measured in this assay, because pro-IL-1p has been reported to be partially active.65 The exceptionally low concentration of IL-1p in cell extracts from one IFN-resistant patient (patient 22) indicates that other growth-promoting mechanisms, such as lack of production of IL-IRA or release of different stimulatory cytokines, may enhance proliferation of the Ph'-positive clone in certain individuals. Similar observations by Rambaldi et a1,66 who described nearly the same mechanism in acute myeloblastic leukemia, and by Otsuka et al, who found IL-1p mRNA in some CML monocyte samples? are in agreement with our results. Our data suggest that overproduction of IL-lp by cells from IFN-resistant CML patients provides the leukemic cells with a growth advantage and is probably a mechanism of disease progression in CML.
To further evaluate whether IL-1 inhibitory molecules affect CML progenitor cell proliferation, we tested the effect of sIL-1R and IL-1RA. sIL-1R is a truncated receptor that exists in solution as a monomer and binds 1 mol IL-1 /mol re~eptor.~' It has been found to be biologically active and it neutralized IL-1 in an animal IL-1RA was recently purified, sequenced, and ~l o n e d .~~,~' This natural inhibitory molecule blocks the binding of IL-la or IL-1p to IL-1 receptors and consequently inhibits different cellular activities that are mediated through binding of these cytokines to their receptor." We found that both sIL-1R and IL-1RA inhibited BFU-E and CFU-GM CML colony proliferation in a dose-dependent fashion and that their effect plateaued at 100 ng/mL and 500 ng/mL, respectively. Colony growth inhibition was more pronounced in cultures from IFN-resistant patients as compared with cultures from hematologically normal individuals ( Table 4 ). The mild inhibitory effect exerted by sIL-1R and IL-lRA on CML progenitors from IFN-sensitive patients suggests that some of the IFN-sensitive cells may be producing their own IL-1RA.
Recent data indicating that IFN inhibits IL-1 synthesis in mononuclear cells stimulated by IL-1'5"7 suggest that the inhibitory mechanisms of IFN in CML include suppression of IL-1. It is therefore possible that overproduction of IL-1 by CMLcells may result in resistance to IFN, and inhibition of IL-1 may increase the efficacy of IFN in CML.
In conclusion, our observations indicate that CML progenitor proliferation may be reduced by blocking the interaction between IL-1p and its receptor. Based on these results, we intend to initiate a clinical trial investigating the use of IL-1RA in the treatment of CML.
